This randomized noninferiority trial compares the effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy (DAPT) on cardiac and cerebrovascular
This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant
项与P2Y12 receptor 相关的药物 Prasugrel Hydrochloride/Aspirin 盐酸普拉格雷/阿司匹林 靶点 COX x P2Y12 receptor 作用机制 COX抑制剂[+1] 在研机构 Torrent Pharmaceuticals Ltd. 原研机构 Torrent Pharmaceuticals Ltd. 在研适应症 急性冠状动脉综合征 非在研适应症- 最高研发阶段批准上市 首次获批国家/地区 印度 ...
NO is an endogenous platelet inhibitor (Freedman, 2008), and platelet sensitivity towards NO is reduced in the presence of P2Y12 receptor activation (Kirkby et al., 2013). As increased ROS formation by platelets may reduce NO availability, this should indirectly increase platelet activation and va...
To define the circulating miRNA response to endotoxemia without common confounders such as medication and co-morbidities in critically-ill sepsis patients, we employed an experimental low-dose endotoxemia model in combination with P2Y12 inhibitor treatment in healthy volunteers. Findings were subsequently ...
Both aspirin (p ≤ 0.05) and 2-methylthioadenosine 5′-monophosphate triethylammonium salt hydrate (P2Y12 inhibitor; p ≤ 0.01) significantly decreased their invasion capacity, and effectively reverted invasion to levels comparable to SK-OV-3 cells alone. Conclusion: While there is increasing ...
However, there is poor evidence on how this compares with administration of a P2Y12 inhibitor after defining coronary anatomy (i.e., downstream administration). Moreover, there are limited head-to-head comparisons of the two P2Y12 inhibitors—ticagrelor and prasugrel—currently recommended by the ...
TSP-1抑制剂; Inhibitor of Thrombospondin (TSP-1) 品牌 上海楚肽生物科技有限公司 1年 查看详情 ￥100.00/毫克 陕西宝鸡 478188-26-0 DX600 ACE2特异性抑制剂 新研博美 陕西新研博美生物科技有限公司 1年 查看详情 面议 上海 高纯度抑制剂 化合物10058-F4 质检保证仅供科研 CAS 403811-55-2 上海陶...
Both aspirin (p ≤ 0.05) and 2-methylthioadenosine 5′-monophosphate triethylammonium salt hydrate (P2Y12 inhibitor; p ≤ 0.01) significantly decreased their invasion capacity, and effectively reverted invasion to levels comparable to SK-OV-3 cells alone. Conclusion: While there is increasing ...
This open-label randomized trial compares the effect of a genotype-guided oral P2Y12 inhibitor selection strategy vs conventional clopidogrel prescribing